nct_id,drug_name,status,phase,start_date,why_stopped
NCT00725231,Doxorubicin,UNKNOWN,PHASE3,,
NCT01321775,Doxorubicin,UNKNOWN,PHASE2,,
NCT04506554,Doxorubicin,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT00903630,Doxorubicin,TERMINATED,"PHASE1,PHASE2",,lack of funding
NCT00309569,Doxorubicin,COMPLETED,PHASE3,,
NCT00309881,Doxorubicin,COMPLETED,PHASE2,,
NCT03452553,Doxorubicin,WITHDRAWN,NA,,"CMS disapproval, no alternative for sites/patient, risk of financial burden."
NCT04654195,Doxorubicin,UNKNOWN,,,
NCT00499018,Doxorubicin,UNKNOWN,PHASE3,,
NCT00949182,Doxorubicin,COMPLETED,PHASE2,,
NCT05936086,Doxorubicin,RECRUITING,NA,,
NCT06944457,Doxorubicin,RECRUITING,PHASE1,,
NCT00002557,Doxorubicin,UNKNOWN,PHASE2,,
NCT02273856,Doxorubicin,TERMINATED,,,The study was terminated due to insufficient subject enrollment and very slow enrollment.
NCT00819351,Doxorubicin,COMPLETED,PHASE3,,
NCT03553537,Doxorubicin,UNKNOWN,PHASE3,,
NCT02456857,Doxorubicin,COMPLETED,PHASE2,,
NCT05411237,Doxorubicin,NOT_YET_RECRUITING,PHASE3,,
NCT00002898,Doxorubicin,COMPLETED,PHASE3,,
NCT00742963,Doxorubicin,COMPLETED,"PHASE1,PHASE2",,
NCT05159193,Doxorubicin,RECRUITING,PHASE3,,
NCT04625907,Doxorubicin,RECRUITING,"PHASE1,PHASE2",,
NCT01185964,Doxorubicin,COMPLETED,"PHASE1,PHASE2",,
NCT00039195,Doxorubicin,COMPLETED,PHASE2,,
NCT05326984,Doxorubicin,UNKNOWN,NA,,
NCT00003038,Doxorubicin,COMPLETED,PHASE1,,
NCT00651755,Doxorubicin,COMPLETED,NA,,
NCT03340376,Doxorubicin,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT00929591,Doxorubicin,COMPLETED,PHASE3,,
NCT00955890,Doxorubicin,TERMINATED,PHASE2,,Enrolled too slow
NCT02548780,Doxorubicin,COMPLETED,NA,,
NCT03407430,Doxorubicin,TERMINATED,PHASE2,,Low patient accrual
NCT01120834,Doxorubicin,COMPLETED,"PHASE1,PHASE2",,
NCT02502266,Doxorubicin,ACTIVE_NOT_RECRUITING,"PHASE2,PHASE3",,
NCT02472353,Doxorubicin,TERMINATED,PHASE2,,did not meet target accrual
NCT02822157,Doxorubicin,UNKNOWN,PHASE2,,
NCT00101101,Doxorubicin,COMPLETED,PHASE2,,
NCT01925612,Doxorubicin,TERMINATED,PHASE2,,Sponsor decision based on portfolio prioritization and changing treatment landscape in frontline DLBCL
NCT03286634,Doxorubicin,RECRUITING,PHASE2,,
NCT02890602,Doxorubicin,COMPLETED,PHASE2,,
NCT02260544,Doxorubicin,COMPLETED,PHASE1,,
NCT00204659,Doxorubicin,COMPLETED,PHASE2,,
NCT03603379,Doxorubicin,COMPLETED,PHASE1,,
NCT06839703,Doxorubicin,NOT_YET_RECRUITING,PHASE1,,
NCT01451580,Doxorubicin,UNKNOWN,PHASE2,,
NCT01051362,Doxorubicin,UNKNOWN,PHASE2,,
NCT00656669,Doxorubicin,COMPLETED,NA,,
NCT03437070,Doxorubicin,WITHDRAWN,PHASE1,,Sponsor Decision
NCT01111903,Doxorubicin,COMPLETED,"PHASE1,PHASE2",,
NCT00055679,Doxorubicin,COMPLETED,PHASE3,,
NCT00005583,Doxorubicin,COMPLETED,PHASE3,,
NCT04134936,Doxorubicin,COMPLETED,PHASE1,,
NCT01120171,Doxorubicin,TERMINATED,PHASE2,,Due to poor accrual
NCT01702129,Doxorubicin,COMPLETED,PHASE1,,
NCT02958163,Doxorubicin,TERMINATED,PHASE2,,lack of recruitment
NCT01036087,Doxorubicin,COMPLETED,PHASE2,,
NCT05899621,Doxorubicin,RECRUITING,,,
NCT00582725,Doxorubicin,COMPLETED,PHASE2,,
NCT01974440,Doxorubicin,COMPLETED,PHASE3,,
NCT07021989,Doxorubicin,NOT_YET_RECRUITING,PHASE2,,
NCT05467670,Doxorubicin,RECRUITING,PHASE2,,
NCT00945009,Doxorubicin,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT02377752,Doxorubicin,COMPLETED,PHASE1,,
NCT04803019,Doxorubicin,UNKNOWN,PHASE3,,
NCT01255514,Doxorubicin,COMPLETED,PHASE2,,
NCT01669239,Doxorubicin,COMPLETED,PHASE2,,
NCT01234519,Doxorubicin,TERMINATED,"PHASE1,PHASE2",,Poor recruitment
NCT01967667,Doxorubicin,COMPLETED,NA,,
NCT04843267,Doxorubicin,UNKNOWN,PHASE2,,
NCT00758732,Doxorubicin,TERMINATED,PHASE2,,Poor accrual
NCT04877821,Doxorubicin,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT03407144,Doxorubicin,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT02141906,Doxorubicin,COMPLETED,PHASE2,,
NCT01678664,Doxorubicin,COMPLETED,PHASE2,,
NCT05281471,Doxorubicin,RECRUITING,PHASE3,,
NCT03971409,Doxorubicin,RECRUITING,PHASE2,,
NCT02142049,Doxorubicin,COMPLETED,"PHASE1,PHASE2",,
NCT02200757,Doxorubicin,COMPLETED,PHASE2,,
NCT01708798,Doxorubicin,TERMINATED,"PHASE2,PHASE3",,Futility
NCT00003640,Doxorubicin,TERMINATED,PHASE2,,low accrual
NCT03356860,Doxorubicin,COMPLETED,"PHASE1,PHASE2",,
NCT06699576,Doxorubicin,NOT_YET_RECRUITING,PHASE1,,
NCT05858710,Doxorubicin,COMPLETED,PHASE1,,
NCT02964260,Doxorubicin,UNKNOWN,NA,,
NCT00038142,Doxorubicin,TERMINATED,PHASE2,,Low Accrual
NCT02331251,Doxorubicin,TERMINATED,"PHASE1,PHASE2",,PI not longer at site.
NCT01338753,Doxorubicin,COMPLETED,PHASE2,,
NCT00730483,Doxorubicin,TERMINATED,NA,,High incidence of biloma and liver abscess after TACE
NCT00187070,Doxorubicin,COMPLETED,NA,,
NCT00581854,Doxorubicin,COMPLETED,PHASE2,,
NCT00129935,Doxorubicin,COMPLETED,PHASE3,,
NCT04650984,Doxorubicin,RECRUITING,PHASE3,,
NCT04969835,Doxorubicin,RECRUITING,PHASE1,,
NCT03719326,Doxorubicin,COMPLETED,PHASE1,,
NCT00331552,Doxorubicin,COMPLETED,"PHASE1,PHASE2",,
NCT00737438,Doxorubicin,COMPLETED,PHASE2,,
NCT00193115,Doxorubicin,COMPLETED,PHASE2,,
NCT01234324,Doxorubicin,COMPLETED,PHASE2,,
NCT01033578,Doxorubicin,UNKNOWN,NA,,
NCT00278408,Doxorubicin,COMPLETED,PHASE3,,
NCT00773383,Erlotinib,TERMINATED,PHASE2,,
NCT01515969,Erlotinib,TERMINATED,PHASE1,,Patient safety - Unacceptable toxicity
NCT00405405,Erlotinib,COMPLETED,PHASE1,,
NCT00137826,Erlotinib,COMPLETED,PHASE2,,
NCT02006043,Erlotinib,UNKNOWN,PHASE2,,
NCT02904850,Erlotinib,UNKNOWN,,,
NCT00564720,Erlotinib,TERMINATED,PHASE2,,Due to poor accrual of the study
NCT00553462,Erlotinib,COMPLETED,PHASE2,,
NCT00137839,Erlotinib,COMPLETED,PHASE2,,
NCT00207077,Erlotinib,COMPLETED,PHASE1,,
NCT01032070,Erlotinib,TERMINATED,PHASE2,,"In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, it has been stopped."
NCT02847377,Erlotinib,COMPLETED,NA,,
NCT00843531,Erlotinib,TERMINATED,PHASE2,,Low Accrual
NCT00585377,Erlotinib,COMPLETED,PHASE2,,
NCT02787447,Erlotinib,UNKNOWN,PHASE2,,
NCT01101334,Erlotinib,COMPLETED,PHASE2,,
NCT02638428,Erlotinib,UNKNOWN,PHASE2,,
NCT01932229,Erlotinib,UNKNOWN,PHASE2,,
NCT04193007,Erlotinib,UNKNOWN,PHASE2,,
NCT00060307,Erlotinib,COMPLETED,PHASE2,,
NCT00881166,Erlotinib,COMPLETED,PHASE1,,
NCT00577707,Erlotinib,COMPLETED,PHASE2,,
NCT00973310,Erlotinib,UNKNOWN,PHASE2,,
NCT00242502,Erlotinib,COMPLETED,PHASE2,,
NCT01103375,Erlotinib,TERMINATED,PHASE1,,Slow accrual
NCT00954226,Erlotinib,COMPLETED,PHASE1,,
NCT00553254,Erlotinib,COMPLETED,PHASE2,,
NCT01535729,Erlotinib,COMPLETED,,,
NCT02770014,Erlotinib,TERMINATED,PHASE2,,Terminated due to Osimertinib approval
NCT00661193,Erlotinib,COMPLETED,PHASE2,,
NCT01068587,Erlotinib,COMPLETED,"PHASE1,PHASE2",,
NCT00281021,Erlotinib,TERMINATED,PHASE2,,Interim analysis revealed that only 1 patient had a partial response.
NCT00536640,Erlotinib,COMPLETED,PHASE2,,
NCT00266097,Erlotinib,COMPLETED,PHASE1,,
NCT00039182,Erlotinib,COMPLETED,PHASE2,,
NCT06675695,Erlotinib,ACTIVE_NOT_RECRUITING,,,
NCT00556712,Erlotinib,COMPLETED,PHASE3,,
NCT00660816,Erlotinib,COMPLETED,PHASE2,,
NCT02364609,Erlotinib,COMPLETED,PHASE1,,
NCT02748707,Erlotinib,UNKNOWN,PHASE2,,
NCT00720356,Erlotinib,COMPLETED,PHASE2,,
NCT00384826,Erlotinib,COMPLETED,PHASE2,,
NCT04007835,Erlotinib,UNKNOWN,NA,,
NCT02954523,Erlotinib,TERMINATED,"PHASE1,PHASE2",,Lack of accrual
NCT00718315,Erlotinib,COMPLETED,PHASE3,,
NCT01180959,Erlotinib,COMPLETED,PHASE2,,
NCT00043823,Erlotinib,COMPLETED,"PHASE1,PHASE2",,
NCT00026338,Erlotinib,COMPLETED,PHASE3,,
NCT02293733,Erlotinib,COMPLETED,,,
NCT00144976,Erlotinib,COMPLETED,NA,,
NCT00954525,Erlotinib,COMPLETED,PHASE1,,
NCT02882984,Erlotinib,UNKNOWN,PHASE3,,
NCT00672243,Erlotinib,COMPLETED,PHASE2,,
NCT01110876,Erlotinib,TERMINATED,"PHASE1,PHASE2",,Unanticipated Toxicities
NCT01377376,Erlotinib,TERMINATED,PHASE3,,
NCT01835938,Erlotinib,UNKNOWN,"PHASE1,PHASE2",,
NCT02926638,Erlotinib,TERMINATED,"PHASE2,PHASE3",,Drug company decided to terminate all sponsored clinical studies involving rilotumumab.
NCT00446225,Erlotinib,COMPLETED,PHASE3,,
NCT01951755,Erlotinib,COMPLETED,,,
NCT00611715,Erlotinib,TERMINATED,PHASE2,,low accrual
NCT01782690,Erlotinib,COMPLETED,,,
NCT00895362,Erlotinib,COMPLETED,PHASE1,,
NCT01137162,Erlotinib,TERMINATED,,,Low Accrual
NCT01123460,Erlotinib,COMPLETED,,,
NCT01416688,Erlotinib,COMPLETED,,,
NCT00883480,Erlotinib,COMPLETED,NA,,
NCT02318368,Erlotinib,TERMINATED,PHASE2,,Sponsor's decision
NCT00301418,Erlotinib,COMPLETED,"PHASE1,PHASE2",,
NCT00642746,Erlotinib,TERMINATED,PHASE2,,Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.
NCT06678230,Erlotinib,NOT_YET_RECRUITING,PHASE2,,
NCT00462995,Erlotinib,COMPLETED,PHASE2,,
NCT01000428,Erlotinib,UNKNOWN,,,
NCT00531934,Erlotinib,COMPLETED,PHASE2,,
NCT01306045,Erlotinib,COMPLETED,PHASE2,,
NCT04045522,Erlotinib,UNKNOWN,,,
NCT02000531,Erlotinib,COMPLETED,PHASE4,,
NCT00337883,Erlotinib,COMPLETED,PHASE2,,
NCT00193622,Erlotinib,COMPLETED,PHASE2,,
NCT00063895,Erlotinib,COMPLETED,"PHASE1,PHASE2",,
NCT00832637,Erlotinib,TERMINATED,PHASE2,,Low accrual
NCT00888511,Erlotinib,COMPLETED,PHASE2,,
NCT00739063,Erlotinib,TERMINATED,PHASE2,,Poor Accrual
NCT00579683,Erlotinib,COMPLETED,,,
NCT00339586,Erlotinib,UNKNOWN,PHASE2,,
NCT00187486,Erlotinib,COMPLETED,PHASE2,,
NCT00536770,Erlotinib,SUSPENDED,PHASE2,,DSMB
NCT01752205,Erlotinib,UNKNOWN,PHASE3,,
NCT03720873,Erlotinib,UNKNOWN,PHASE2,,
NCT01211483,Erlotinib,COMPLETED,"PHASE1,PHASE2",,
NCT02468661,Erlotinib,TERMINATED,PHASE1,,Major challenge for enrollment of participants.
NCT00975767,Erlotinib,TERMINATED,PHASE1,,"The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no patients enrolled in Phase 2."
NCT00656136,Erlotinib,COMPLETED,PHASE3,,
NCT02155465,Erlotinib,COMPLETED,"PHASE1,PHASE2",,
NCT00227032,Erlotinib,TERMINATED,PHASE1,,Loss of funding
NCT00367601,Erlotinib,COMPLETED,PHASE2,,
NCT01116336,Erlotinib,COMPLETED,PHASE1,,
NCT00254384,Erlotinib,COMPLETED,PHASE1,,
NCT00671970,Erlotinib,COMPLETED,PHASE2,,
NCT00570258,Erlotinib,TERMINATED,PHASE2,,"FDA approved higher dose of study drug. Dose used in protocol lower than SOC - enrollment stopped, those on treatment were given option to opt out."
NCT02080078,Erlotinib,TERMINATED,PHASE1,,REB decision
NCT01503502,Imatinib,UNKNOWN,PHASE2,,
NCT03639922,Imatinib,UNKNOWN,PHASE3,,
NCT00048672,Imatinib,COMPLETED,PHASE2,,
NCT02847377,Imatinib,COMPLETED,NA,,
NCT00782834,Imatinib,TERMINATED,PHASE2,,"Stopped early for futility, unable to meet accrual goals"
NCT01460498,Imatinib,COMPLETED,PHASE1,,
NCT06175702,Imatinib,NOT_YET_RECRUITING,,,
NCT01440959,Imatinib,COMPLETED,PHASE2,,
NCT00324077,Imatinib,WITHDRAWN,PHASE1,,Insufficient Enrollment
NCT02127372,Imatinib,TERMINATED,"PHASE1,PHASE2",,The study was closed due to poor accrual
NCT00030667,Imatinib,COMPLETED,PHASE2,,
NCT01751919,Imatinib,COMPLETED,PHASE1,,
NCT02638428,Imatinib,UNKNOWN,PHASE2,,
NCT03205267,Imatinib,UNKNOWN,PHASE2,,
NCT00538109,Imatinib,COMPLETED,NA,,
NCT00112775,Imatinib,UNKNOWN,PHASE2,,
NCT00061945,Imatinib,COMPLETED,"PHASE1,PHASE2",,
NCT00707408,Imatinib,COMPLETED,PHASE2,,
NCT00499889,Imatinib,TERMINATED,PHASE2,,Support issue.
NCT03674099,Imatinib,UNKNOWN,PHASE2,,
NCT00094029,Imatinib,APPROVED_FOR_MARKETING,,,
NCT00493181,Imatinib,COMPLETED,PHASE2,,
NCT00615927,Imatinib,COMPLETED,PHASE2,,
NCT01175109,Imatinib,UNKNOWN,PHASE1,,
NCT03241199,Imatinib,UNKNOWN,PHASE2,,
NCT05905887,Imatinib,RECRUITING,PHASE2,,
NCT02272777,Imatinib,COMPLETED,PHASE3,,
NCT01460693,Imatinib,COMPLETED,PHASE3,,
NCT07091019,Imatinib,NOT_YET_RECRUITING,,,
NCT00425646,Imatinib,COMPLETED,PHASE2,,
NCT02954523,Imatinib,TERMINATED,"PHASE1,PHASE2",,Lack of accrual
NCT04409223,Imatinib,TERMINATED,PHASE3,,R\&D strategy adjustment
NCT01004497,Imatinib,COMPLETED,PHASE2,,
NCT01810718,Imatinib,COMPLETED,PHASE1,,
NCT00763763,Imatinib,COMPLETED,PHASE2,,
NCT01933906,Imatinib,COMPLETED,PHASE1,,
NCT02352558,Imatinib,COMPLETED,PHASE1,,
NCT00455221,Imatinib,COMPLETED,PHASE1,,
NCT02607332,Imatinib,COMPLETED,PHASE2,,
NCT01216085,Imatinib,COMPLETED,PHASE2,,
NCT00920868,Imatinib,COMPLETED,PHASE1,,
NCT00075218,Imatinib,COMPLETED,PHASE3,,
NCT04330690,Imatinib,UNKNOWN,PHASE3,,
NCT00881049,Imatinib,COMPLETED,PHASE2,,
NCT01126814,Imatinib,COMPLETED,"PHASE1,PHASE2",,
NCT03996096,Imatinib,COMPLETED,,,
NCT06889168,Imatinib,RECRUITING,PHASE1,,
NCT01048320,Imatinib,COMPLETED,PHASE1,,
NCT03454503,Imatinib,COMPLETED,,,
NCT03844360,Imatinib,RECRUITING,PHASE4,,
NCT04006769,Imatinib,COMPLETED,EARLY_PHASE1,,
NCT00702689,Imatinib,COMPLETED,PHASE2,,
NCT00079313,Imatinib,COMPLETED,PHASE2,,
NCT02398825,Imatinib,TERMINATED,PHASE2,,low enrollment rate
NCT05245968,Imatinib,RECRUITING,PHASE1,,
NCT02897245,Imatinib,UNKNOWN,,,
NCT03885830,Imatinib,COMPLETED,,,
NCT06336395,Imatinib,RECRUITING,PHASE2,,
NCT00324987,Imatinib,TERMINATED,PHASE3,,The trial failed to accrue
NCT01690065,Imatinib,UNKNOWN,PHASE2,,
NCT04598009,Imatinib,RECRUITING,PHASE2,,
NCT01568645,Imatinib,WITHDRAWN,PHASE1,,
NCT00219765,Imatinib,TERMINATED,"PHASE1,PHASE2",,
NCT05381753,Imatinib,COMPLETED,,,
NCT00150072,Imatinib,COMPLETED,PHASE2,,
NCT00362466,Imatinib,TERMINATED,PHASE3,,Insufficient Enrollment
NCT00760981,Imatinib,COMPLETED,PHASE1,,
NCT00352677,Imatinib,COMPLETED,PHASE1,,
NCT03624530,Imatinib,UNKNOWN,"PHASE2,PHASE3",,
NCT01073644,Imatinib,TERMINATED,,,The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no safety concerns that led to the decision to terminate.
NCT00861471,Imatinib,TERMINATED,"PHASE1,PHASE2",,due to slow accrual
NCT00510653,Imatinib,COMPLETED,PHASE2,,
NCT00444795,Imatinib,COMPLETED,,,
NCT00769782,Imatinib,COMPLETED,PHASE2,,
NCT00511069,Imatinib,COMPLETED,PHASE2,,
NCT04129931,Imatinib,COMPLETED,PHASE2,,
NCT00054431,Imatinib,COMPLETED,PHASE2,,
NCT02269267,Imatinib,COMPLETED,PHASE2,,
NCT00793871,Imatinib,COMPLETED,PHASE4,,
NCT01126892,Imatinib,COMPLETED,PHASE3,,
NCT02130557,Imatinib,COMPLETED,PHASE3,,
NCT02495519,Imatinib,COMPLETED,PHASE2,,
NCT03891901,Imatinib,COMPLETED,PHASE2,,
NCT00253565,Imatinib,COMPLETED,PHASE1,,
NCT00156286,Imatinib,COMPLETED,PHASE2,,
NCT00171977,Imatinib,COMPLETED,PHASE4,,
NCT01762969,Imatinib,UNKNOWN,PHASE2,,
NCT00896129,Imatinib,COMPLETED,,,
NCT03381053,Imatinib,UNKNOWN,,,
NCT00506831,Imatinib,COMPLETED,"PHASE1,PHASE2",,
NCT00085475,Imatinib,COMPLETED,PHASE2,,
NCT01738139,Imatinib,COMPLETED,PHASE1,,
NCT00075400,Imatinib,COMPLETED,PHASE2,,
NCT02326311,Imatinib,COMPLETED,PHASE3,,
NCT07061145,Imatinib,RECRUITING,,,
NCT00376467,Imatinib,COMPLETED,PHASE2,,
NCT01281865,Imatinib,COMPLETED,"PHASE1,PHASE2",,
NCT07096609,Imatinib,NOT_YET_RECRUITING,"PHASE1,PHASE2",,
NCT00583115,Imatinib,TERMINATED,PHASE2,,Unable to enroll subjects
NCT02812693,Imatinib,WITHDRAWN,"PHASE1,PHASE2",,poor accrual
NCT01321775,Trastuzumab,UNKNOWN,PHASE2,,
NCT00068757,Trastuzumab,COMPLETED,PHASE1,,
NCT05980481,Trastuzumab,ACTIVE_NOT_RECRUITING,"PHASE2,PHASE3",,
NCT06331169,Trastuzumab,RECRUITING,PHASE1,,
NCT05203601,Trastuzumab,COMPLETED,PHASE1,,
NCT05349383,Trastuzumab,COMPLETED,,,
NCT01937117,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT02244580,Trastuzumab,COMPLETED,NA,,
NCT06251401,Trastuzumab,RECRUITING,NA,,
NCT06483386,Trastuzumab,NOT_YET_RECRUITING,PHASE2,,
NCT03006172,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE1,,
NCT05159193,Trastuzumab,RECRUITING,PHASE3,,
NCT00433407,Trastuzumab,COMPLETED,NA,,
NCT00955890,Trastuzumab,TERMINATED,PHASE2,,Enrolled too slow
NCT01238029,Trastuzumab,TERMINATED,PHASE1,,"new methods of treatment, no more patients appilicable for study"
NCT06994377,Trastuzumab,RECRUITING,,,
NCT06767436,Trastuzumab,RECRUITING,,,
NCT00629499,Trastuzumab,COMPLETED,PHASE2,,
NCT07093931,Trastuzumab,NOT_YET_RECRUITING,PHASE4,,
NCT04605575,Trastuzumab,UNKNOWN,PHASE2,,
NCT02638428,Trastuzumab,UNKNOWN,PHASE2,,
NCT01912963,Trastuzumab,TERMINATED,PHASE2,,The study terminated early due to weak accrual.
NCT04014075,Trastuzumab,COMPLETED,PHASE2,,
NCT00317720,Trastuzumab,COMPLETED,"PHASE1,PHASE2",,
NCT05594082,Trastuzumab,UNKNOWN,,,
NCT05356897,Trastuzumab,WITHDRAWN,PHASE2,,no sites were regulatory ready and the SC took the study to a different group.
NCT01432886,Trastuzumab,COMPLETED,PHASE1,,
NCT05553522,Trastuzumab,RECRUITING,PHASE1,,
NCT00272987,Trastuzumab,TERMINATED,PHASE3,,Enrollment was closed after the open label stage due to poor recruitment rate (randomized stage never opened).
NCT05253651,Trastuzumab,RECRUITING,PHASE3,,
NCT01364493,Trastuzumab,COMPLETED,PHASE2,,
NCT05765357,Trastuzumab,COMPLETED,PHASE1,,
NCT04329065,Trastuzumab,RECRUITING,PHASE2,,
NCT05803889,Trastuzumab,UNKNOWN,,,
NCT01439191,Trastuzumab,COMPLETED,PHASE2,,
NCT01928290,Trastuzumab,COMPLETED,PHASE2,,
NCT04439110,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT06481553,Trastuzumab,ACTIVE_NOT_RECRUITING,,,
NCT01669239,Trastuzumab,COMPLETED,PHASE2,,
NCT02144012,Trastuzumab,TERMINATED,PHASE3,,
NCT05193292,Trastuzumab,UNKNOWN,PHASE2,,
NCT03696771,Trastuzumab,COMPLETED,PHASE1,,
NCT02214004,Trastuzumab,UNKNOWN,PHASE2,,
NCT00512993,Trastuzumab,COMPLETED,PHASE3,,
NCT00964704,Trastuzumab,WITHDRAWN,PHASE2,,No patients have been recruited therefore study has been cancelled
NCT04983238,Trastuzumab,COMPLETED,"PHASE1,PHASE2",,
NCT03321981,Trastuzumab,COMPLETED,PHASE2,,
NCT07073755,Trastuzumab,RECRUITING,,,
NCT00485979,Trastuzumab,COMPLETED,PHASE2,,
NCT02062983,Trastuzumab,SUSPENDED,,,Difficulty in enrolling patients
NCT03765983,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT04120246,Trastuzumab,SUSPENDED,PHASE1,,Study placed on hold.
NCT03168880,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT03014076,Trastuzumab,COMPLETED,PHASE1,,
NCT02199418,Trastuzumab,COMPLETED,PHASE2,,
NCT06731478,Trastuzumab,RECRUITING,PHASE3,,
NCT05945368,Trastuzumab,UNKNOWN,PHASE2,,
NCT03323424,Trastuzumab,WITHDRAWN,PHASE2,,No patient enrolled during the authorized period
NCT02152943,Trastuzumab,COMPLETED,PHASE1,,
NCT00331552,Trastuzumab,COMPLETED,"PHASE1,PHASE2",,
NCT01921335,Trastuzumab,COMPLETED,PHASE1,,
NCT01084876,Trastuzumab,COMPLETED,PHASE3,,
NCT03024450,Trastuzumab,COMPLETED,,,
NCT00496808,Trastuzumab,COMPLETED,NA,,
NCT01329640,Trastuzumab,TERMINATED,PHASE2,,
NCT01423123,Trastuzumab,COMPLETED,PHASE1,,
NCT03365882,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT03412643,Trastuzumab,UNKNOWN,PHASE2,,
NCT01513408,Trastuzumab,UNKNOWN,NA,,
NCT06537674,Trastuzumab,NOT_YET_RECRUITING,,,
NCT00567190,Trastuzumab,COMPLETED,PHASE3,,
NCT06680596,Trastuzumab,ENROLLING_BY_INVITATION,PHASE2,,
NCT07049133,Trastuzumab,NOT_YET_RECRUITING,,,
NCT00047255,Trastuzumab,COMPLETED,PHASE3,,
NCT00005926,Trastuzumab,COMPLETED,PHASE2,,
NCT06174987,Trastuzumab,RECRUITING,PHASE3,,
NCT04983121,Trastuzumab,RECRUITING,PHASE2,,
NCT05755048,Trastuzumab,RECRUITING,PHASE3,,
NCT07047755,Trastuzumab,NOT_YET_RECRUITING,PHASE2,,
NCT03153163,Trastuzumab,COMPLETED,PHASE1,,
NCT00896376,Trastuzumab,COMPLETED,NA,,
NCT00429299,Trastuzumab,COMPLETED,PHASE2,,
NCT03975647,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT05978648,Trastuzumab,RECRUITING,PHASE2,,
NCT04188548,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE1,,
NCT00004074,Trastuzumab,COMPLETED,PHASE1,,
NCT04903652,Trastuzumab,COMPLETED,PHASE2,,
NCT02725424,Trastuzumab,COMPLETED,PHASE2,,
NCT01597414,Trastuzumab,COMPLETED,PHASE2,,
NCT05078190,Trastuzumab,ACTIVE_NOT_RECRUITING,,,
NCT02135159,Trastuzumab,COMPLETED,PHASE1,,
NCT02063724,Trastuzumab,COMPLETED,PHASE1,,
NCT04457596,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT05346224,Trastuzumab,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT07130344,Trastuzumab,NOT_YET_RECRUITING,NA,,
NCT01904903,Trastuzumab,COMPLETED,PHASE2,,
NCT05346861,Trastuzumab,UNKNOWN,PHASE3,,
NCT05997524,Trastuzumab,COMPLETED,PHASE2,,
NCT01300962,Trastuzumab,COMPLETED,PHASE1,,
NCT04509596,Trastuzumab,COMPLETED,PHASE1,,
NCT05226728,Pembrolizumab,COMPLETED,PHASE1,,
NCT04219254,Pembrolizumab,RECRUITING,"PHASE1,PHASE2",,
NCT04901741,Pembrolizumab,NOT_YET_RECRUITING,PHASE2,,
NCT04638582,Pembrolizumab,RECRUITING,PHASE2,,
NCT05775289,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT02708641,Pembrolizumab,COMPLETED,PHASE2,,
NCT05296772,Pembrolizumab,UNKNOWN,PHASE1,,
NCT05410145,Pembrolizumab,RECRUITING,"PHASE1,PHASE2",,
NCT04739202,Pembrolizumab,UNKNOWN,PHASE2,,
NCT05541445,Pembrolizumab,UNKNOWN,"PHASE1,PHASE2",,
NCT06793215,Pembrolizumab,RECRUITING,PHASE3,,
NCT02757391,Pembrolizumab,TERMINATED,PHASE1,,Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
NCT04724018,Pembrolizumab,RECRUITING,"PHASE1,PHASE2",,
NCT02999477,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE1,,
NCT06711900,Pembrolizumab,RECRUITING,PHASE3,,
NCT05809336,Pembrolizumab,COMPLETED,"PHASE2,PHASE3",,
NCT04165798,Pembrolizumab,RECRUITING,,,
NCT03419481,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT04119830,Pembrolizumab,WITHDRAWN,PHASE2,,implementation issues
NCT03815630,Pembrolizumab,UNKNOWN,EARLY_PHASE1,,
NCT02575807,Pembrolizumab,TERMINATED,"PHASE1,PHASE2",,Study was stopped due to low enrollment and lack of clinical activity.
NCT04153734,Pembrolizumab,NOT_YET_RECRUITING,PHASE2,,
NCT07163507,Pembrolizumab,NOT_YET_RECRUITING,,,
NCT02730546,Pembrolizumab,COMPLETED,"PHASE1,PHASE2",,
NCT04179110,Pembrolizumab,WITHDRAWN,PHASE2,,Funding was withdrawn prior to first enrollment.
NCT06484920,Pembrolizumab,RECRUITING,PHASE2,,
NCT02900560,Pembrolizumab,TERMINATED,PHASE2,,
NCT04165096,Pembrolizumab,COMPLETED,PHASE2,,
NCT02855203,Pembrolizumab,COMPLETED,"PHASE1,PHASE2",,
NCT04099641,Pembrolizumab,COMPLETED,PHASE2,,
NCT04999202,Pembrolizumab,TERMINATED,PHASE1,,"Last patient ongoing on treatment ended the study on 20th January 2025. Hence, the end of study was reached as defined in the protocol."
NCT05714553,Pembrolizumab,TERMINATED,"PHASE1,PHASE2",,The NuTide:303 study was terminated at NuCana's discretion due to refinement of the pipeline strategy. The overall risk benefit assessment of NUC-3373 remains positive and future NUC-3373 studies are under consideration.
NCT06772623,Pembrolizumab,RECRUITING,"PHASE1,PHASE2",,
NCT02940496,Pembrolizumab,COMPLETED,PHASE2,,
NCT03145961,Pembrolizumab,UNKNOWN,PHASE2,,
NCT06929286,Pembrolizumab,RECRUITING,PHASE3,,
NCT04869137,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT06385080,Pembrolizumab,RECRUITING,"PHASE1,PHASE2",,
NCT04624113,Pembrolizumab,TERMINATED,PHASE1,,Ipsen bought out Epizyme
NCT03996473,Pembrolizumab,TERMINATED,PHASE1,,LPLV reached on 30Jan2023. Study was closed early for feasibility reasons related to enrollment of first line IO na√Øve patients. Safety data is consistent with the known safety profile of both drugs and no new safety issues have been observed
NCT06780111,Pembrolizumab,RECRUITING,"PHASE1,PHASE2",,
NCT05189171,Pembrolizumab,COMPLETED,,,
NCT03354936,Pembrolizumab,UNKNOWN,,,
NCT05218629,Pembrolizumab,UNKNOWN,PHASE2,,
NCT02621398,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE1,,
NCT04336098,Pembrolizumab,COMPLETED,PHASE1,,
NCT02703714,Pembrolizumab,COMPLETED,PHASE2,,
NCT06128863,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT02892201,Pembrolizumab,TERMINATED,PHASE2,,Low enrollment
NCT06482801,Pembrolizumab,RECRUITING,PHASE2,,
NCT07207928,Pembrolizumab,ACTIVE_NOT_RECRUITING,,,
NCT03093428,Pembrolizumab,COMPLETED,PHASE2,,
NCT03348891,Pembrolizumab,COMPLETED,NA,,
NCT07021989,Pembrolizumab,NOT_YET_RECRUITING,PHASE2,,
NCT05389527,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT05467670,Pembrolizumab,RECRUITING,PHASE2,,
NCT06045195,Pembrolizumab,NOT_YET_RECRUITING,PHASE2,,
NCT03051672,Pembrolizumab,TERMINATED,PHASE2,,"Based on two-stage design, the study ended at stage 1 with no evidence of promise based on pre-specified decision rule."
NCT02925533,Pembrolizumab,TERMINATED,PHASE1,,Terminated due to safety concerns.
NCT03217071,Pembrolizumab,COMPLETED,PHASE2,,
NCT03225547,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT02301039,Pembrolizumab,COMPLETED,PHASE2,,
NCT06311981,Pembrolizumab,RECRUITING,PHASE2,,
NCT04083599,Pembrolizumab,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",,
NCT02312557,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT02644967,Pembrolizumab,COMPLETED,PHASE2,,
NCT03407144,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT02364609,Pembrolizumab,COMPLETED,PHASE1,,
NCT06004336,Pembrolizumab,RECRUITING,PHASE2,,
NCT02079636,Pembrolizumab,COMPLETED,PHASE1,,
NCT05182164,Pembrolizumab,RECRUITING,PHASE2,,
NCT01174121,Pembrolizumab,RECRUITING,PHASE2,,
NCT03358472,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT06005818,Pembrolizumab,RECRUITING,PHASE2,,
NCT06268613,Pembrolizumab,RECRUITING,PHASE1,,
NCT05969496,Pembrolizumab,RECRUITING,PHASE2,,
NCT04949191,Pembrolizumab,TERMINATED,PHASE2,,A business decision due to availability of commercial drug and other options for accessing study drug treatment.
NCT06196554,Pembrolizumab,RECRUITING,,,
NCT03053856,Pembrolizumab,UNKNOWN,PHASE2,,
NCT02331251,Pembrolizumab,TERMINATED,"PHASE1,PHASE2",,PI not longer at site.
NCT02316002,Pembrolizumab,COMPLETED,PHASE2,,
NCT03411473,Pembrolizumab,TERMINATED,PHASE2,,Trial will not proceed due to changes in the treatment landscape.
NCT02448303,Pembrolizumab,COMPLETED,PHASE2,,
NCT04387461,Pembrolizumab,COMPLETED,PHASE2,,
NCT03166254,Pembrolizumab,WITHDRAWN,PHASE1,,Lost funding
NCT04157517,Pembrolizumab,TERMINATED,"PHASE1,PHASE2",,Study was terminated early due to futility.
NCT03114280,Pembrolizumab,WITHDRAWN,"PHASE1,PHASE2",,MSD would not able to support the study's continuation after protocol modifications required by ANSM through dose de-escalation of pembrolizumab
NCT06731478,Pembrolizumab,RECRUITING,PHASE3,,
NCT05116189,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT04585035,Pembrolizumab,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",,
NCT06266338,Pembrolizumab,RECRUITING,PHASE2,,
NCT05929768,Pembrolizumab,RECRUITING,PHASE3,,
NCT04862455,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT05425576,Pembrolizumab,NOT_YET_RECRUITING,PHASE2,,
NCT03752723,Pembrolizumab,COMPLETED,"PHASE1,PHASE2",,
NCT04740996,Pembrolizumab,UNKNOWN,,,
NCT05558982,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT04581824,Pembrolizumab,TERMINATED,PHASE2,,"Trial terminated by GSK for strategic reasons, after all participants completed treatment. This decision was not based on a safety concern"
NCT05945823,Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT06875310,Pembrolizumab,RECRUITING,PHASE3,,
NCT05297565,Nivolumab,COMPLETED,PHASE3,,
NCT04506554,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT04988841,Nivolumab,COMPLETED,PHASE2,,
NCT03726281,Nivolumab,WITHDRAWN,PHASE2,,End of Agreement between BMS and SGHL
NCT04431635,Nivolumab,TERMINATED,PHASE1,,Loss of study funding
NCT03065179,Nivolumab,COMPLETED,PHASE2,,
NCT03443856,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT03700905,Nivolumab,UNKNOWN,PHASE3,,
NCT05361434,Nivolumab,ACTIVE_NOT_RECRUITING,,,
NCT03169764,Nivolumab,WITHDRAWN,"PHASE1,PHASE2",,Trial not initiated
NCT03340129,Nivolumab,RECRUITING,PHASE2,,
NCT04173325,Nivolumab,TERMINATED,PHASE1,,Closed by the IRB 5/26/22 due to non-compliance
NCT04907539,Nivolumab,COMPLETED,PHASE2,,
NCT03575234,Nivolumab,WITHDRAWN,PHASE1,,funding and drug were withdrawn
NCT04654234,Nivolumab,COMPLETED,,,
NCT02696993,Nivolumab,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",,
NCT06365619,Nivolumab,RECRUITING,PHASE2,,
NCT03825367,Nivolumab,UNKNOWN,"PHASE1,PHASE2",,
NCT07163507,Nivolumab,NOT_YET_RECRUITING,,,
NCT04570839,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT04078295,Nivolumab,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",,
NCT05361720,Nivolumab,RECRUITING,PHASE2,,
NCT04299880,Nivolumab,COMPLETED,PHASE1,,
NCT06999980,Nivolumab,NOT_YET_RECRUITING,PHASE2,,
NCT03793166,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE3,,
NCT04624113,Nivolumab,TERMINATED,PHASE1,,Ipsen bought out Epizyme
NCT02873962,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT05189171,Nivolumab,COMPLETED,,,
NCT03354936,Nivolumab,UNKNOWN,,,
NCT03219671,Nivolumab,UNKNOWN,PHASE2,,
NCT03396211,Nivolumab,COMPLETED,PHASE1,,
NCT06452329,Nivolumab,ACTIVE_NOT_RECRUITING,,,
NCT03929029,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE1,,
NCT06587451,Nivolumab,SUSPENDED,PHASE3,,"In light of the evolving regulatory landscape and growing indications that major Health Authorities will move towards a streamlined clinical development, Sandoz took a strategic decision and is winding down its CJPB898A12301 clinical study."
NCT03575598,Nivolumab,COMPLETED,EARLY_PHASE1,,
NCT03807765,Nivolumab,COMPLETED,PHASE1,,
NCT03502330,Nivolumab,COMPLETED,PHASE1,,
NCT03529890,Nivolumab,UNKNOWN,PHASE2,,
NCT07028125,Nivolumab,RECRUITING,PHASE4,,
NCT03348891,Nivolumab,COMPLETED,NA,,
NCT02864316,Nivolumab,TERMINATED,PHASE2,,Poor accrual
NCT02983006,Nivolumab,COMPLETED,PHASE1,,
NCT03835533,Nivolumab,COMPLETED,PHASE1,,
NCT02304458,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT03048136,Nivolumab,WITHDRAWN,PHASE3,,Business objective has changed
NCT03507699,Nivolumab,COMPLETED,PHASE1,,
NCT02275533,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT03610711,Nivolumab,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",,
NCT06410534,Nivolumab,WITHDRAWN,PHASE2,,PI left NIH.
NCT03267498,Nivolumab,COMPLETED,PHASE2,,
NCT03241173,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT06196554,Nivolumab,RECRUITING,,,
NCT04871594,Nivolumab,COMPLETED,PHASE1,,
NCT03283046,Nivolumab,WITHDRAWN,PHASE1,,Similar to another study.
NCT03692442,Nivolumab,UNKNOWN,,,
NCT04062656,Nivolumab,UNKNOWN,PHASE2,,
NCT03459222,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT04233840,Nivolumab,UNKNOWN,"PHASE1,PHASE2",,
NCT02714218,Nivolumab,COMPLETED,PHASE3,,
NCT03251924,Nivolumab,TERMINATED,"PHASE1,PHASE2",,Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.
NCT03647878,Nivolumab,ACTIVE_NOT_RECRUITING,,,
NCT06304597,Nivolumab,NOT_YET_RECRUITING,PHASE1,,
NCT07075120,Nivolumab,NOT_YET_RECRUITING,PHASE1,,
NCT02038933,Nivolumab,COMPLETED,PHASE2,,
NCT04966676,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT03656718,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT04024878,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE1,,
NCT02954991,Nivolumab,TERMINATED,PHASE2,,This study was terminated as a result of Sponsor portfolio reprioritization.
NCT04702880,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT06926179,Nivolumab,RECRUITING,,,
NCT02451982,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT06773910,Nivolumab,RECRUITING,PHASE2,,
NCT02488759,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT05926960,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT03404960,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT04046614,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT03563248,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT01658878,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT04270864,Nivolumab,TERMINATED,PHASE1,,The part A of the trial has been completed according to the protocol. The part B has not been opened because of unfeasibility (experimental products not yet available).
NCT06283238,Nivolumab,NOT_YET_RECRUITING,,,
NCT02681302,Nivolumab,TERMINATED,"PHASE1,PHASE2",,Lack of Accrual
NCT03458455,Nivolumab,UNKNOWN,,,
NCT03068455,Nivolumab,COMPLETED,PHASE3,,
NCT06544655,Nivolumab,RECRUITING,PHASE1,,
NCT02526017,Nivolumab,COMPLETED,PHASE1,,
NCT06566391,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT04271384,Nivolumab,COMPLETED,PHASE2,,
NCT03014804,Nivolumab,WITHDRAWN,PHASE2,,Final contract negotiations
NCT02967133,Nivolumab,TERMINATED,PHASE2,,Lack of enrollment
NCT04599140,Nivolumab,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",,
NCT04688658,Nivolumab,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",,
NCT07050043,Nivolumab,RECRUITING,PHASE3,,
NCT05233358,Nivolumab,UNKNOWN,NA,,
NCT03333616,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
NCT03326258,Nivolumab,WITHDRAWN,"PHASE1,PHASE2",,The study itself was Disapproved on 04/20/2018 and will not be moving forward.
NCT02960906,Nivolumab,COMPLETED,PHASE2,,
NCT02041533,Nivolumab,COMPLETED,PHASE3,,
NCT02419417,Nivolumab,COMPLETED,"PHASE1,PHASE2",,
NCT05704647,Nivolumab,RECRUITING,PHASE2,,
NCT03313804,Nivolumab,ACTIVE_NOT_RECRUITING,PHASE2,,
